Shu Li

The safety of ustekinumab treatment in patients with moderate‐to‐severe psoriasis and latent tuberculosis infection

M. Song, Y. Wasfi, Y. Shen, 2012, The British journal of dermatology.

Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study

A. Paller, M. Song, L. Eichenfield, 2020, The British journal of dermatology.